Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon-alpha + retinoic acid
- Development stage
- Unknown
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
Interferon-alpha + retinoic acid is a combination therapy consisting of two agents with distinct but complementary mechanisms. Interferon-alpha (IFN-α) is a cytokine with immunomodulatory, antiproliferative, and antiangiogenic properties. Retinoic acids (such as 13-cis-retinoic acid or all-trans-retinoic acid) are vitamin A derivatives that regulate cell differentiation and proliferation. The combination has demonstrated synergistic effects in preclinical models and clinical trials for various cancers—including advanced squamous cell carcinoma of the skin and renal cell carcinoma—by enhancing malignant cell differentiation, inhibiting tumor growth, and modulating immune responses[1][2][3][4][5][6].
- Brand names
- RoferonAccutane
- Other names
- interferon-alpha and retinoic acidIFN-alpha + retinoic acidinterferon alpha-2a + 13-cis-retinoic acidinterferon alpha-2a + all-trans-retinoic acid
02
Targets
RARA (Retinoic acid receptor alpha)IFNAR (Immune system modulation via type I interferon receptor)RXRA (Retinoid X receptor alpha)
Beyond the preview
Go deeper on interferon-alpha + retinoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon-alpha + retinoic acid.